Marcelo Figari

Marcelo Figari

Auto-generated profile, based on publicly available information

Marcelo Figari

Hospital Italiano de Buenos Aires

Research Focus & Metrics

Academic Career Length

16Years (2011-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2019 in JAMA Otolaryngology–Head & Neck Surgery
Verified
Journal Article
Closed access
PDF file
LBLuis Alejandro Boccalatte
Luis Alejandro Boccalatte
FHFelipe Higuera
Felipe Higuera
NGNatalia Lucía Gómez
Natalia Lucía Gómez
ATAlejandro Yanzón de la Torre
Alejandro Yanzón de la Torre
EMEduardo Luis Mazzaro
Eduardo Luis Mazzaro
MFMarcelo Fernando Figari
Marcelo Fernando Figari
Importance Identifying parathyroid glands correctly before a surgical procedure is essential to perform minimally invasive surgery. First-line tests with discordant or negative results underscore the need for more accurate imaging tests, thus decreasing the requirement for bilateral neck exploration or reintervention. Objective To review the available evidence to determine positive predictive value, negative predictive value, sensitivity, and specificity in clinical cases in which18F-fluorocholine positron emission tomography–computed tomography (PET/CT) could be useful as a method to locate the lesions, and the benefits and controversial aspects of the method. Evidence Review A search was conducted using the PubMed Central and Cochrane Library databases for studies published in English from July 26, 2014, to November 30, 2018, using the search terms18 choline,18F choline,18F-choline,18 fluorocholine PET CT,hyperparathyroidism,primary hyperparathyroidism,secondary hyperparathyroidism,tertiary hyperparathyroidism,persistent hyperparathyroidism,recurrent hyperparathyroidism,ectopic hyperparathyroidism, andparathyroid adenoma. Other inclusion criteria were reporting at least 1 of the following measurements: negative or positive predictive value, sensitivity, and specificity of18F-fluorocholine PET/CT in the diagnosis of hyperparathyroidism (HPT). Exclusion criteria were language other than English, use of a tracer other than18F-fluorocholine, reports of a single case, and studies not related to HPT. The Oxford Centre classifications for levels of evidence were used. Findings Sixteen studies fulfilled the inclusion criteria, comprising a total of 619 patients. Selected studies included 10 prospective cohort studies, 5 retrospective cohort studies, and 1 case series. Of the subtypes of HPT diagnosed using18F-fluorocholine PET/CT, 579 were primary HPT, 22 were secondary HPT, 1 was tertiary HPT, and 7 were associated with multiple endocrine neoplasia type I. Pathologically, the neoplasms comprised 459 adenomas, 59 hyperplasia, and 19 double adenomas. Conclusions and Relevance 18F-fluorcholine PET/CT may be indicated when results of first-line tests are negative or discordant and in challenging clinical situations where locating the source of HPT is difficult.

1 November 2020 in JCO Global Oncology
Verified
Journal Article
Open access
RARenata Abrahão
Renata Abrahão
SPSandra Perdomo
Sandra Perdomo
LPLuis Felipe Ribeiro Pinto
Luis Felipe Ribeiro Pinto
FCFlávia Nascimento de Carvalho
Flávia Nascimento de Carvalho
FDFernando Luis Dias
Fernando Luis Dias
OGon behalf of the InterCHANGE Group
on behalf of the InterCHANGE Group
PURPOSE: Head and neck squamous cell carcinoma (HNSCC) incidence is high in South America, where recent data on survival are sparse. We investigated the main predictors of HNSCC survival in Brazil, Argentina, Uruguay, and Colombia. METHODS: Sociodemographic and lifestyle information was obtained from standardized interviews, and clinicopathologic data were extracted from medical records and pathologic reports. The Kaplan-Meier method and Cox regression were used for statistical analyses. RESULTS: Of 1,463 patients, 378 had a larynx cancer (LC), 78 hypopharynx cancer (HC), 599 oral cavity cancer (OC), and 408 oropharynx cancer (OPC). Most patients (55.5%) were diagnosed with stage IV disease, ranging from 47.6% for LC to 70.8% for OPC. Three-year survival rates were 56.0% for LC, 54.7% for OC, 48.0% for OPC, and 37.8% for HC. In multivariable models, patients with stage IV disease had approximately 7.6 (LC/HC), 11.7 (OC), and 3.5 (OPC) times higher mortality than patients with stage I disease. Current and former drinkers with LC or HC had approximately 2 times higher mortality than never-drinkers. In addition, older age at diagnosis was independently associated with worse survival for all sites. In a subset analysis of 198 patients with OPC with available human papillomavirus (HPV) type 16 data, those with HPV-unrelated OPC had a significantly worse 3-year survival compared with those with HPV-related OPC (44.6% v 75.6%, respectively), corresponding to a 3.4 times higher mortality. CONCLUSION: Late stage at diagnosis was the strongest predictor of lower HNSCC survival. Early cancer detection and reduction of harmful alcohol use are fundamental to decrease the high burden of HNSCC in South America.

1 September 2020 in American Journal of Otolaryngology
Verified
Journal Article
Closed access
DSDavid Smith
David Smith
JMJuan Montagne
Juan Montagne
MRMicaela Raices
Micaela Raices
ADAgustín Dietrich
Agustín Dietrich
IBIndalecio Carboni Bisso
Indalecio Carboni Bisso
MFMarcelo Figari
Marcelo Figari

1 May 2020 in American Journal of Otolaryngology
Verified
Journal Article
Closed access
LBL.A. Boccalatte
L.A. Boccalatte
JLJ.J. Larrañaga
J.J. Larrañaga
GRG.M. Perez Raffo
G.M. Perez Raffo
CTC.A. Teijido
C.A. Teijido
GFG. García Fornari
G. García Fornari
MFM.F. Figari
M.F. Figari

6 June 2018 in World Journal of Surgery
Verified
Journal Article
Closed access
PDF file
DSDavid A. Shaye
David A. Shaye
TTTravis Tollefson
Travis Tollefson
ISIrfan Shah
Irfan Shah
GKGopal Krishnan
Gopal Krishnan
DMDamir Matic
Damir Matic
WSWarren Schubert
Warren Schubert

9 June 2020 in Oral and Maxillofacial Surgery
Verified
Journal Article
Closed access
PDF file
LBL. A. Boccalatte
L. A. Boccalatte
MNM. G. Nassif
M. G. Nassif
MFM. F. Figari
M. F. Figari
NGN. L. Gómez
N. L. Gómez
MAM. C. Argibay
M. C. Argibay
LRL. E. Ritacco
L. E. Ritacco